Stevan Djakovic

Stevan Djakovic is an accomplished clinical researcher with extensive experience in the development of anti-cancer therapies. Currently serving as Senior Director of Clinical Research at ArriVent Biopharma, Stevan previously held the position of Senior Director of Clinical Science at Nurix Therapeutics, focusing on a novel BTK degrader for hematological cancers. During tenure at Genentech, Stevan advanced through multiple roles, contributing to the early clinical development of innovative immunotherapies and cancer vaccines for various cancer types. Earlier experience includes significant contributions to early-stage clinical development initiatives at Cleave Biosciences and foundational research roles at UC San Diego. Stevan holds a PhD in Biology with a focus on neurobiology from UC San Diego and has a solid publication record in the field.